Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

UNC Lineberger Researchers Discover Experimental Compound to Block Lymphoma

The University of North Carolina (UNC) Lineberger Comprehensive Cancer Center researchers have discovered a hyperactive cell that contributes to tumor growth in primary effusion lymphoma and a potential treatment strategy to block down its downstream effects.

The primary effusion lymphoma is a highly aggressive subtype of non-Hodgkin lymphoma, a type of blood cancer involving abnormally growing white blood cells. The researchers also developed an experimental therapeutic, UNC3810A, to block the signal and slow tumor growth.

Besides this, researchers also found a protein called Tyro3 that’s highly upregulated and expressed in a subtype of non-Hodgkin lymphoma, called primary effusion lymphoma. Researchers also developed a compound that targeted Tyro3 and found that it killed primary effusion lymphoma cells and tumors.

UNC Lineberger’s Blossom Damania, Ph.D., vice dean for research in the UNC School of Medicine, Wong, Johnson, and Wang, other authors included Timothy J Stuhlmiller, Louise C. Giffin, Carolina Lin, Rachele Bigi, Jichen Zhao, Weihe Zhang, Ariana G Bravo Cruz, Steven Park, H Shelton Earp, Dirk P Dittmer, and Stephen V Frye.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024